Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emtricitabine vs Stavudine in Antiretroviral-Naive HIV-1 Infected Patients
NCT00006208Phase 3Unknown
- Sponsor
- Triangle Pharmaceuticals, Inc.
- Start
- Aug 2000
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of emtricitabine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Triangle Pharmaceuticals, Inc. Primary endpoint: Persistent Virological Response (HIV-1 RNA <= 50 or 400 copies/mL) at 60 weeks. Status: unknown.
02
Drugs
emtricitabine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00006208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006208.